{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:37:34Z","timestamp":1791509854958,"version":"4.3.4"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Sertraline is a common first-line pharmacological treatment of Major Depressive Disorder (MDD). There is no established consensus nor clinical guidelines for personalized dose adjustments, which imply risks of toxicity and lack of efficacy. To address these challenges, there is preliminary evidence of the clinical utility of the determination of blood levels of sertraline by means of therapeutic drug monitoring (TDM). Further evidence is needed regarding the optimal therapeutic range of sertraline in terms of an optimal efficacy\/tolerability-safety balance, with need of prospective studies on the association between blood concentration of sertraline and clinical outcomes. The PREDEP-SERT study (PREdictors of response in DEPression treated with SERTraline) is a single-center, observational, longitudinal, ambispective cohort study of patients with MDD to investigate the association between blood concentration of sertraline and its effectiveness, tolerability and safety (pre-registered study in Spain, REec number: 0014-2022-OBS, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/reec.aemps.es\/reec\/observacional\/0014-2022-OBS\" xlink:type=\"simple\">https:\/\/reec.aemps.es\/reec\/observacional\/0014-2022-OBS<\/jats:ext-link>). It adopts wide inclusion and exclusion criteria in order to allow the inclusion of patients that are representative of real-world clinical practice. It includes an exploratory retrospective subcohort and a subsequent 6-month follow-up prospective subcohort, with repeated measures (blood concentrations of sertraline and clinical outcomes) at scheduled timepoints (15 days, 30 days, 60 days, 90 days and 6 months). Relevant clinical, pharmacogenetic and sociodemographic potential predictors, confounders and effect modifiers will be explored. Its primary objective is to prospectively assess the association between blood concentration of sertraline (and the ratio with its metabolite, N-desmethylsertraline) and the intensity of depressive symptoms measured by the Hamilton Depression Rating Scale at 6 months of treatment. Other secondary objectives are to assess the association between blood concentration of sertraline\/N-desmethylsertraline and clinical variables of effectiveness (by means of validated clinical scales) and side effects at every timepoint. Its results may elucidate the clinical utility of TDM in the therapeutic management of MDD in a personalized fashion.<\/jats:p>","DOI":"10.1371\/journal.pone.0325335","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T17:23:02Z","timestamp":1754673782000},"page":"e0325335","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["The PREDEP-SERT study protocol: A 6-month follow-up cohort study of predictors of effectiveness, tolerability and safety of sertraline for depression using Therapeutic Drug Monitoring"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-9635","authenticated-orcid":true,"given":"Patricio","family":"Molero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2349-3631","authenticated-orcid":true,"given":"Covadonga","family":"Canga-Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Tapia-Alzuguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pablo","family":"Bullard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Unceta-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Aub\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge M.","family":"N\u00fa\u00f1ez-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Aldaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"pone.0325335.ref001","unstructured":"World Health Organization. Depressive disorder (depression). 2023 [cited 2 May 2025]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"pone.0325335.ref002","first-page":"3","article-title":"The increasing burden of depression","volume":"7","author":"J-P L\u00e9pine","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pone.0325335.ref003","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222 Published: 29 June 2022. 2022 [cited 15 Apr 2025]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng222\/chapter\/Recommendations#treatment-for-a-new-episode-of-more-severe-depression"},{"issue":"9","key":"pone.0325335.ref004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023\u00a0: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"RW Lam","year":"2024","journal-title":"Can J Psychiatry"},{"issue":"4","key":"pone.0325335.ref005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other antidepressive agents for depression","author":"A Cipriani","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"pone.0325335.ref006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major depression","volume":"18","author":"MC Mauri","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"pone.0325335.ref007","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0278-5846(01)00314-1","article-title":"Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels","volume":"26","author":"MC Mauri","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"pone.0325335.ref008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"pone.0325335.ref009","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jad.2025.03.017","article-title":"The real-world safety profile of sertraline: Pharmacovigilance analysis of the FAERS database","volume":"379","author":"Y Shu","year":"2025","journal-title":"J Affect Disord"},{"key":"pone.0325335.ref010","volume-title":"ICD-10: international statistical classification of diseases and related health problems: tenth revision","author":"World Health Organization","year":"2016","edition":"2"},{"key":"pone.0325335.ref011","unstructured":"Spanish Agency of Medicines and Medical Devices. Official drug label of sertraline. [cited 25 Mar 2023]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/59735\/FT_59735.html"},{"key":"pone.0325335.ref012","unstructured":"OneOme\u00ae. [cited 15 Apr 2025]. Available from: https:\/\/oneome.com\/home-international\/"},{"issue":"1","key":"pone.0325335.ref013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"M Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0325335.ref014","first-page":"324","article-title":"Validaci\u00f3n de la versi\u00f3n castellana de la escala de Hamilton para la depresi\u00f3n","volume":"14","author":"JA Ramos-Brieva","year":"1986","journal-title":"Actas Luso Esp Neurol Psiquiatr Cienc Afines"},{"key":"pone.0325335.ref015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"SA Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"13","key":"pone.0325335.ref016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0025-7753(02)72429-9","article-title":"Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales","volume":"118","author":"A Lobo","year":"2002","journal-title":"Med Clin (Barc)"},{"key":"pone.0325335.ref017","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"AT Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"pone.0325335.ref018","first-page":"217","article-title":"Adaptaci\u00f3n castellana de la escala de evaluaci\u00f3n conductual para la depresi\u00f3n de Beck","volume":"12","author":"V Conde","year":"1975","journal-title":"Rev Psiquiatr Psicol Med Eur Am"},{"issue":"1","key":"pone.0325335.ref019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"M Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"pone.0325335.ref020","volume-title":"Early clinical drug evaluation (ECDEU) assessment manual","author":"W Guy","year":"1976"},{"issue":"12","key":"pone.0325335.ref021","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"K Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"pone.0325335.ref022","first-page":"134","article-title":"Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS)","volume":"9","author":"S Al-Halab\u00ed","year":"2016","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"11","key":"pone.0325335.ref023","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"WK Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"pone.0325335.ref024","first-page":"30","article-title":"Validation of a version in Spanish of the Yale-Brown Obsessive-Compulsive Scale","volume":"30","author":"JM Vega-Dienstmaier","year":"2002","journal-title":"Actas Esp Psiquiatr"},{"issue":"3","key":"pone.0325335.ref025","first-page":"189","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"MF Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"20","key":"pone.0325335.ref026","first-page":"767","article-title":"Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population","volume":"112","author":"A Lobo","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"pone.0325335.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"O Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"3","key":"pone.0325335.ref028","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","article-title":"Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses","volume":"42","author":"K Thompson","year":"2000","journal-title":"Schizophr Res"},{"issue":"3","key":"pone.0325335.ref029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0168-8510(92)90004-U","article-title":"The QLDS: a scale for the measurement of quality of life in depression","volume":"22","author":"SM Hunt","year":"1992","journal-title":"Health Policy"},{"issue":"7","key":"pone.0325335.ref030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0924-9338(99)00230-8","article-title":"The development and validation of a Spanish version of the quality of life in depression scale (QLDS)","volume":"14","author":"S Cervera-Enguix","year":"1999","journal-title":"Eur Psychiatry"},{"key":"pone.0325335.ref031","volume-title":"Banco de instrumentos b\u00e1sicos para la pr\u00e1ctica de la psiquiatr\u00eda clinica","author":"MP Garc\u00eda-Portilla","year":"2022"},{"key":"pone.0325335.ref032","unstructured":"World Health Organization. 2020. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/healthy-diet"},{"key":"pone.0325335.ref033","unstructured":"STROBE Initiative. [cited 10 May 2025]. Available from: http:\/\/www.strobe-statement.org"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T17:23:08Z","timestamp":1754673788000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325335"}},"subtitle":[],"editor":[{"given":"Dickens","family":"Akena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325335","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}